Thyrocare Technologies Ltd. has fixed June 23, 2026, as the record date for its proposed final dividend of ₹7 per share for FY26.
The dividend, recommended by the board at its meeting on May 7, 2026, is subject to shareholder approval at the company’s annual general meeting scheduled for June 30, 2026.
The proposed payout comes on top of the ₹7 interim dividend declared in October 2025 and already paid to shareholders. With that, the company’s total dividend for FY26 stands at ₹14 per share.
Shares of Thyrocare, which has a market capitalisation of ₹8,450.09 crore, were trading at ₹530.90, up 2.21 percent from the previous close of ₹519.40. The stock touched an intraday high of ₹533.45 and a low of ₹525.80.
FY26 dividend payout
For FY26, shareholders are set to receive:
- Interim dividend: ₹7 per share
- Final dividend: ₹7 per share
- Total dividend: ₹14 per share
On a face value of ₹10, the total payout represents a 70 percent dividend for the financial year.
At the current market price, the annual dividend translates into a yield of around 1.9 percent.
The company has also issued details of the tax deduction at source (TDS) framework applicable to the final dividend.
For resident shareholders:
- 10 percent TDS will apply if valid PAN details are available.
- Shareholders without a valid PAN or with an inoperative PAN may face 20 percent TDS.
For non-resident shareholders, including FIIs and FPIs:
- 20 percent TDS, along with surcharge and cess, will apply.
- Eligible investors may claim benefits under applicable Double Tax Avoidance Agreements (DTAA), subject to documentation requirements.
Shareholders seeking concessional tax treatment must submit the required documents through the company’s compliance portal by 6 p.m. on June 26, 2026.
Q4 FY26 performance
The dividend recommendation follows improved financial performance during FY26.
During the fourth quarter, the company reported revenue growth of around 9.2 percent year-on-year. Demand for its Aarogyam preventive healthcare packages supported growth.
Thyrocare also maintained EBITDA margins of nearly 25 percent, despite increasing competition in the diagnostics industry.
Expansion and operations
The company operates a centralized hub-and-spoke model, which allows large sample volumes to be processed through its laboratory network.
During FY26, Thyrocare expanded its network by adding several Regional Processing Laboratories (RPLs) aimed at reducing turnaround times.
Following its acquisition by API Holdings, the parent company of PharmEasy, Thyrocare has expanded its business-to-business diagnostic processing operations and increased utilization at its central laboratory in Navi Mumbai.
About the company
Thyrocare Technologies is a diagnostic services provider offering preventive healthcare tests, pathology services and wellness screening solutions through a nationwide network of laboratories and franchise partners.
TL;DR:
Thyrocare has set June 23 as the record date for its proposed ₹7 final dividend. Including the interim dividend paid earlier, the company’s total FY26 payout stands at ₹14 per share. Shareholders will vote on the proposal at the AGM on June 30.
AI summary:
- Thyrocare fixed June 23 as the record date for its final dividend.
- The proposed final dividend is ₹7 per share.
- Total FY26 dividend payout stands at ₹14 per share.
- Shareholders will approve the dividend at the June 30 AGM.
- TDS-related documentation must be submitted by June 26.
